GAMMA Investing’s LENZ Therapeutics LENZ Stock Holding History

GAMMA Investing’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76K	Buy	486 +58	+14%	+$467	﹤0.01%	3668
2026 Q1	$3.92K	Buy	428 +174	+69%	+$2.44K	﹤0.01%	3454
2025 Q4	$4.06K	Sell	254 -58	-19%	-$1.69K	﹤0.01%	3367
2025 Q3	$14.5K	Buy	312 +25	+9%	+$919	﹤0.01%	2688
2025 Q2	$8.41K	Buy	287 +60	+26%	+$1.63K	﹤0.01%	2899
2025 Q1	$5.84K	Buy	227 +118	+108%	+$2.91K	﹤0.01%	3023
2024 Q4	$3.15K	Buy	109 +27	+33%	+$823	﹤0.01%	3073
2024 Q3	$1.95K	Buy	82 +51	+165%	+$1.13K	﹤0.01%	3077
2024 Q2	$536	Buy	+31	New	+$542	﹤0.01%	3199

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

GAMMA Investing's LENZ Position: Q2 2026 in Review

GAMMA Investing increased its LENZ Therapeutics (LENZ) stake by 14% in Q2 2026, buying an estimated $467 and bringing the position to 486 shares worth $2.76K. The position accounts for ﹤0.01% of the portfolio, ranked #3668.

GAMMA Investing first reported a position in LENZ in Q2 2024 and has held it in 9 quarters since. The position peaked at $14.5K in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

GAMMA Investing held 486 shares of LENZ Therapeutics worth $2.76K as of Q2 2026.
GAMMA Investing bought 58 LENZ Therapeutics shares in Q2 2026, an estimated $467.
LENZ Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3668 holding.
GAMMA Investing first reported a position in LENZ Therapeutics in Q2 2024 and has held it in 9 quarters since.
GAMMA Investing's LENZ Therapeutics position peaked at $14.5K in Q3 2025.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.